Table 1.
Patient and treatment characteristics.
| All Groups | BM | PBSC | SUCB | DUCB | P-value | |
|---|---|---|---|---|---|---|
| N=202 | N=32 | N=75 | N=21 | N=74 | ||
| Patient sex | 0.77 | |||||
| Female | 73 (36.1%) | 14 (43.8%) | 25 (33.3%) | 8 (38.1%) | 26 (35.1%) | |
| Age at HCT (yrs) | <0.01* | |||||
| Median (range) | 50.9 (1.3– 72.8) | 36.1 (1.6–69.4) | 57.0 (21.2–72.8) | 9.4 (2.3–70.7) | 53.6 (1.3–71.9) | |
| Age group (yrs) | <0.01* | |||||
| 0–18 | 40 (19.8%) | 11 (34.4%) | 0 | 18 (85.7%) | 11 (14.9%) | |
| 18–45 | 41 (20.3%) | 7 (21.9%) | 16 (21.3%) | 1 (4.8%) | 17 (23.0%) | |
| >=45 | 121 (59.9%) | 14 (43.8%) | 59 (78.7%) | 2 (9.5%) | 46 (62.2%) | |
| Follow up time (days) | 0.81 | |||||
| Median (range) | 741.0 (33.0–2229.0) | 737.5 (39.0–2159.0) | 736.0 (33.0–1974.0) | 728.0 (37.0–2229.0) | 762.5 (34.0–1967.0) | |
| Disease | <0.01* | |||||
| ALL | 46 (22.8%) | 7 (21.9%) | 9 (12.0%) | 15 (71.4%) | 15 (20.3%) | |
| AML | 66 (32.7%) | 5 (15.6%) | 29 (38.7%) | 0 | 32 (43.2%) | |
| CML | 10 (5.0%) | 8 (25.0%) | 1 (1.3%) | 0 | 1 (1.4%) | |
| Other Leukemia | 10 (5.0%) | 1 (3.1%) | 4 (5.3%) | 0 | 5 (6.8%) | |
| Myelodysplasia | 32 (15.8%) | 2 (6.3%) | 15 (20.0%) | 3 (14.3%) | 12 (16.2%) | |
| Non-Hodgkin Lymphoma | 17 (8.4%) | 3 (9.4%) | 8 (10.7%) | 3 (14.3%) | 3 (4.1%) | |
| Hodgkin Lymphoma | 10 (5.0%) | 2 (6.3%) | 5 (6.7%) | 0 | 3 (4.1%) | |
| Myeloproliferative Disease | 1 (0.5%) | 1 (3.1%) | 0 | 0 | 0 | |
| Multiple Myeloma | 10 (5.0%) | 3 (9.4%) | 4 (5.3%) | 0 | 3 (4.1%) | |
| Disease risk group | 0.37 | |||||
| Standard | 109 (54.0%) | 14 (43.8%) | 38 (50.7%) | 12 (57.1%) | 45 (60.8%) | |
| High | 93 (46.0%) | 18 (56.3%) | 37 (49.3%) | 9 (42.9%) | 29 (39.2%) | |
| Timefrom diagnosis to HCT(months) | 0.02* | |||||
| Median (range) | 6.5 (2.0–376.7) | 13.2 (3.5–76.6) | 6.1 (2.0–125.9) | 25.1 (3.0–76.3) | 4.9 (2.3–376.7) | |
| Recipient CMV status | 0.22 | |||||
| Positive | 105 (52.0%) | 16 (50.0%) | 33 (44.0%) | 13 (61.9%) | 43 (58.1%) | |
| Negative | 96 (47.5%) | 16 (50.0%) | 42 (56.0%) | 7 (33.3%) | 31 (41.9%) | |
| Missing | 1(0.5%) | 0 | 0 | 1 (4.8%) | 0 | |
| Conditioning intensity | <0.01* | |||||
| Myeloablative | 81 (40.1%) | 16 (50.0%) | 20 (26.7%) | 19 (90.5%) | 26 (35.1%) | |
| Reduced intensity | 121 (59.9%) | 16 (50.0%) | 55 (73.3%) | 2 (9.5%) | 48 (64.9%) | |
| GVHD prophylaxis | <0.01* | |||||
| CSA/MMF | 112 (55.4%) | 9 (28.1%) | 38 (50.7%) | 17 (81.0%) | 48 (64.9%) | |
| CSA/MMF+ATG | 32 (15.8%) | 7 (21.9%) | 14 (18.7%) | 3 (14.3%) | 8 (10.8%) | |
| CSA/MTX | 41 (20.3%) | 16 (50.0%) | 23 (30.7%) | 1 (4.8%) | 1 (1.4%) | |
| SIRO/MMF | 17 (8.4%) | 0 | 0 | 0 | 17 (23.0%) | |
| ATG | 0.43 | |||||
| Yes | 32 (15.8%) | 7 (21.9%) | 14 (18.7%) | 3 (14.3%) | 8 (10.8%) | |
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ATG, anti-thymocyte globulin; BM, bone marrow; CML, chronic myeloid leukemia; CMV, cytomegalovirus; CSA, cyclosporine; DUCB, double umbilical cord blood; GVHD, graft versus host disease; HCT, hematopoietic cell transplantation; MMF, mycophenolate mofetil; MTX, methotrexate; PBSC, peripheral blood stem cells; SIRO, sirolimus; SUCB, single umbilical cord blood.
*
P-value < 0.05